SCHEMBL3525558

SCHEMBL3525558

Fc1cs[c]c1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177773 0.72
SCHEMBL277538 0.71
SCHEMBL18938764 0.67
SCHEMBL18938655 0.61
SCHEMBL8049697 0.59
SCHEMBL353919 0.59 HSD11B1 (0.30)
SCHEMBL3696888 0.59
SCHEMBL1177771 0.56
SCHEMBL2464341 0.55
SCHEMBL8572573 0.54

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117881662-A Herbicide malonamide containing monocyclic heteroaromatic ring 巴斯夫欧洲公司 2024-04-12 CN disclosed
US-9957248-B2 Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators BAYER CROPSCIENCE AKTIENGESELLSHAFT (DE) 2018-05-01 US disclosed
US-20170166549-A1 Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators BAYER CROPSCIENCE AKTIENGESELLSHAFT (DE) 2017-06-15 US disclosed
US-7652063-B2 For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis ALLERGAN, INC. (US) 2010-01-26 US disclosed
US-7238841-B2 Polymer-supported phosphorus ligands for catalysts E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-07-03 US disclosed
US-7169807-B2 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists ALLERGAN, INC. (US) 2007-01-30 US disclosed
US-20070010495-A1 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS ALLERGAN, INC. (US) 2007-01-11 US disclosed
US-7098261-B2 Polymer-supported phosphorus ligands for catalysis E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-08-29 US disclosed
WO-2005100339-A1 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS ALLERGAN, INC. (US) 2005-10-27 WO disclosed
US-20050228185-A1 For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis ALLERGAN, INC. (US) 2005-10-13 US disclosed
US-6630604-B1 Phosphine and phosphine oxide ligands are prepared using polymeric supports. These compounds can be easily cleaved from the support, and along with the corresponding supported compounds, used as ligands in the preparation of novel, E. I. DU PONT DE NEMOURS AND COMPANY 2003-10-07 US disclosed